General Information of Drug (ID: DMF8O62)

Drug Name
SAVX-1 Drug Info
Indication
Disease Entry ICD 11 Status REF
Central nervous system disease 8A04-8D87 Investigative [1]
Cross-matching ID
TTD Drug ID
DMF8O62

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [2]
MBX-8025 DMNTCV4 Obesity 5B81 Phase 2/3 [3]
T3D-959 DMR3245 Alzheimer disease 8A20 Phase 2 [4]
T3D-959 DMR3245 Alzheimer disease 8A20 Phase 2 [5]
KD3010 DMNFDYE Metabolic disorder 5C50-5D2Z Phase 1 [6]
SAR351034 DM15PG9 Dyslipidemia 5C80-5C81 Phase 1 [7]
CER-002 DMLBKZV Dyslipidemia 5C80-5C81 Phase 1 [8]
PMID25416646-Compound-Figure5-C DM17FKL N. A. N. A. Patented [9]
GW-501516 DMPL2KM Type-1 diabetes 5A10 Discontinued in Phase 4 [10]
Sodelglitazar DMJ816F Hyperlipidaemia 5C80 Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Peroxisome proliferator-activated receptor delta (PPARD) TT2JWF6 PPARD_HUMAN Modulator [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 594).
2 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
3 ClinicalTrials.gov (NCT00701883) Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol. U. S. National Institute of Health. 2008.
4 Phrma report (2013 Alzheimers disease)
5 T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016;51(1):123-38.
6 Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007.
7 Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
8 Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol. 2010 May; 30(5): 894-899.
9 PPAR ligands and their therapeutic applications: a patent review (2008 - 2014).Expert Opin Ther Pat. 2015 Feb;25(2):175-91.
10 Lipid effects of peroxisome proliferator-activated receptor- agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.Arterioscler Thromb Vasc Biol.2012 Sep;32(9):2289-94.
11 Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar. Protein Pept Lett. 2011 Oct;18(10):1021-7.